Ex Vivo Lung Perfusion and Allograft Failure After Lung Transplantation: A National Target Trial Emulation

OBJECTIVE: Ex vivo lung perfusion (EVLP) has been championed as a disruptive strategy to expand the lung transplantation (LT) donor pool, yet contemporary evidence remains limited. Using a real-world cohort, we emulated a randomized controlled trial (RCT) to characterize the causal effect of EVLP on post-LT survival. METHODS: LT recipients ≥18 years were identified from the 2018-2025 Organ Procurement and Transplantation Network. Annual hospital LT volume was computed; centers in the top quartile (>54 LT/y) were designated high-volume centers (HVCs). Using target trial emulation with clone-censor-weight methodology, we simulated a pragmatic, open-label RCT comparing EVLP with standard allografts at HVCs and non-HVCs. Survival was evaluated using Kaplan-Meier and multivariable Cox models. RESULTS: Among 20,627 LTs, 1419 (7%) received EVLP allografts. The proportion of EVLP allografts increased across all centers, from 5% in 2018 to 10% in 2024 and 8% in 2025 (P trend <0.001). In the Lung Allocation Score era, LT using EVLP allografts yielded similar 2-year outcomes at HVC, but inferior outcomes at non-HVC. In the Composite Allocation Score period, however, EVLP was associated with significantly worse survival at non-HVC. In the emulated RCT among CAS-era recipients, EVLP remained independently associated with similar outcomes at HVC, but increased 2-year hazards of patient mortality (HR: 2.43, CI: 1.36-4.34, P=0.003) and allograft failure at non-HVC (HR: 2.52, CI: 1.31-4.84, P=0.005). CONCLUSIONS: EVLP was associated with comparable survival at HVC but inferior outcomes at non-HVC. These findings highlight the critical role of hospital context and center experience in determining the effectiveness and safety of EVLP and call for standardization of protocols across centers.

Authors

Institutions

Publication Details

Journal
Annals of Surgery
Published
2026-11-17
DOI
https://doi.org/10.1097/sla.0000000000007203
Primary Topic
Transplantation: Methods and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ex Vivo Lung Perfusion and Allograft Failure After Lung Transplantation: A National Target Trial Emulation

Richard Jay Shemin, Peyman Benharash, Deep Mehta, Yas Sanaiha et al.
3 links
Annals of Surgery
Transplantation: Methods and Outcomes
article

Ex Vivo Lung Perfusion and Allograft Failure After Lung Transplantation: A National Target Trial Emulation

Richard Jay Shemin, Peyman Benharash, Deep Mehta, Yas Sanaiha, Syed Shahyan Bakhtiyar, Sara Sakowitz
article en

Abstract

OBJECTIVE: Ex vivo lung perfusion (EVLP) has been championed as a disruptive strategy to expand the lung transplantation (LT) donor pool, yet contemporary evidence remains limited. Using a real-world cohort, we emulated a randomized controlled trial (RCT) to characterize the causal effect of EVLP on post-LT survival. METHODS: LT recipients ≥18 years were identified from the 2018-2025 Organ Procurement and Transplantation Network. Annual hospital LT volume was computed; centers in the top quartile (>54 LT/y) were designated high-volume centers (HVCs). Using target trial emulation with clone-censor-weight methodology, we simulated a pragmatic, open-label RCT comparing EVLP with standard allografts at HVCs and non-HVCs. Survival was evaluated using Kaplan-Meier and multivariable Cox models. RESULTS: Among 20,627 LTs, 1419 (7%) received EVLP allografts. The proportion of EVLP allografts increased across all centers, from 5% in 2018 to 10% in 2024 and 8% in 2025 (P trend <0.001). In the Lung Allocation Score era, LT using EVLP allografts yielded similar 2-year outcomes at HVC, but inferior outcomes at non-HVC. In the Composite Allocation Score period, however, EVLP was associated with significantly worse survival at non-HVC. In the emulated RCT among CAS-era recipients, EVLP remained independently associated with similar outcomes at HVC, but increased 2-year hazards of patient mortality (HR: 2.43, CI: 1.36-4.34, P=0.003) and allograft failure at non-HVC (HR: 2.52, CI: 1.31-4.84, P=0.005). CONCLUSIONS: EVLP was associated with comparable survival at HVC but inferior outcomes at non-HVC. These findings highlight the critical role of hospital context and center experience in determining the effectiveness and safety of EVLP and call for standardization of protocols across centers.

Annals of Surgery
University of California, Los Angeles (US), University of Utah (US), University of California System (US), Massachusetts General Hospital (US)
Good health and well-being
Transplantation: Methods and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon